Patient adherence to medication requirements for therapy of type 2 diabetes

C.J. Bailey, M. Kodack

Research output: Contribution to journalArticle

Abstract

Type 2 diabetes is a complex, progressive endocrine and metabolical disease that typically requires substantial lifestyle changes and multiple medications to lower blood glucose, reduce cardiovascular risk and address comorbidities. Despite an extensive range of available and effective treatments, <50% of patients achieve a glycaemical target of HbA <7.0% and about two-thirds die of premature cardiovascular disease. Adherence to prescribed therapies is an important factor in the management of type 2 diabetes that is often overlooked. Inadequate adherence to oral antidiabetes agents, defined as collecting <80% of prescribed medication, is variously estimated to apply to between 36% and 93% of patients. All studies affirm that a significant proportion of type 2 diabetes patients exhibit poor adherence that will contribute to less than desired control. Identified factors that impede adherence include complex dosing regimens, clinical inertia, safety concerns, socioeconomic issues, ethnicity, patient education and beliefs, social support and polypharmacy. This review explores these factors and potential strategies to improve adherence in patients with type 2 diabetes.
Original languageEnglish
Pages (from-to)314-322
Number of pages9
JournalInternational Journal of Clinical Practice
Volume65
Issue number3
Early online date14 Feb 2011
DOIs
Publication statusPublished - Mar 2011

Fingerprint

Patient Compliance
Type 2 Diabetes Mellitus
Endocrine System Diseases
Polypharmacy
Patient Education
Therapeutics
Social Support
Blood Glucose
Life Style
Comorbidity
Cardiovascular Diseases
Safety

Cite this

@article{f9bcfc5e7e224a4e9db300a5a2b54158,
title = "Patient adherence to medication requirements for therapy of type 2 diabetes",
abstract = "Type 2 diabetes is a complex, progressive endocrine and metabolical disease that typically requires substantial lifestyle changes and multiple medications to lower blood glucose, reduce cardiovascular risk and address comorbidities. Despite an extensive range of available and effective treatments, <50{\%} of patients achieve a glycaemical target of HbA <7.0{\%} and about two-thirds die of premature cardiovascular disease. Adherence to prescribed therapies is an important factor in the management of type 2 diabetes that is often overlooked. Inadequate adherence to oral antidiabetes agents, defined as collecting <80{\%} of prescribed medication, is variously estimated to apply to between 36{\%} and 93{\%} of patients. All studies affirm that a significant proportion of type 2 diabetes patients exhibit poor adherence that will contribute to less than desired control. Identified factors that impede adherence include complex dosing regimens, clinical inertia, safety concerns, socioeconomic issues, ethnicity, patient education and beliefs, social support and polypharmacy. This review explores these factors and potential strategies to improve adherence in patients with type 2 diabetes.",
author = "C.J. Bailey and M. Kodack",
year = "2011",
month = "3",
doi = "10.1111/j.1742-1241.2010.02544.x",
language = "English",
volume = "65",
pages = "314--322",
journal = "International Journal of Clinical Practice",
issn = "1368-5031",
publisher = "Wiley-Blackwell",
number = "3",

}

Patient adherence to medication requirements for therapy of type 2 diabetes. / Bailey, C.J.; Kodack, M.

In: International Journal of Clinical Practice, Vol. 65, No. 3, 03.2011, p. 314-322.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Patient adherence to medication requirements for therapy of type 2 diabetes

AU - Bailey, C.J.

AU - Kodack, M.

PY - 2011/3

Y1 - 2011/3

N2 - Type 2 diabetes is a complex, progressive endocrine and metabolical disease that typically requires substantial lifestyle changes and multiple medications to lower blood glucose, reduce cardiovascular risk and address comorbidities. Despite an extensive range of available and effective treatments, <50% of patients achieve a glycaemical target of HbA <7.0% and about two-thirds die of premature cardiovascular disease. Adherence to prescribed therapies is an important factor in the management of type 2 diabetes that is often overlooked. Inadequate adherence to oral antidiabetes agents, defined as collecting <80% of prescribed medication, is variously estimated to apply to between 36% and 93% of patients. All studies affirm that a significant proportion of type 2 diabetes patients exhibit poor adherence that will contribute to less than desired control. Identified factors that impede adherence include complex dosing regimens, clinical inertia, safety concerns, socioeconomic issues, ethnicity, patient education and beliefs, social support and polypharmacy. This review explores these factors and potential strategies to improve adherence in patients with type 2 diabetes.

AB - Type 2 diabetes is a complex, progressive endocrine and metabolical disease that typically requires substantial lifestyle changes and multiple medications to lower blood glucose, reduce cardiovascular risk and address comorbidities. Despite an extensive range of available and effective treatments, <50% of patients achieve a glycaemical target of HbA <7.0% and about two-thirds die of premature cardiovascular disease. Adherence to prescribed therapies is an important factor in the management of type 2 diabetes that is often overlooked. Inadequate adherence to oral antidiabetes agents, defined as collecting <80% of prescribed medication, is variously estimated to apply to between 36% and 93% of patients. All studies affirm that a significant proportion of type 2 diabetes patients exhibit poor adherence that will contribute to less than desired control. Identified factors that impede adherence include complex dosing regimens, clinical inertia, safety concerns, socioeconomic issues, ethnicity, patient education and beliefs, social support and polypharmacy. This review explores these factors and potential strategies to improve adherence in patients with type 2 diabetes.

UR - http://www.scopus.com/inward/record.url?scp=79951631623&partnerID=8YFLogxK

UR - http://onlinelibrary.wiley.com/doi/10.1111/j.1742-1241.2010.02544.x/abstract

U2 - 10.1111/j.1742-1241.2010.02544.x

DO - 10.1111/j.1742-1241.2010.02544.x

M3 - Article

AN - SCOPUS:79951631623

VL - 65

SP - 314

EP - 322

JO - International Journal of Clinical Practice

JF - International Journal of Clinical Practice

SN - 1368-5031

IS - 3

ER -